Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

In collaboration with Roche, we expect results from the Phase 2b PADOVA clinical trial evaluating prasinezumab for Parkinson's disease in 4Q 2024 and with Novo Nordisk, we expect results from the ...

REPLY: Thank you for your eagle-eyed attention to detail and for bringing the inconsistency to our attention regarding the SPECT reconstruction display between 2 articles published in the June 2023 ...

MONTREAL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. ("HPQ” or the "Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a ...

NAPLES, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with ...

Stand Up To Cancer ® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, ...

Louis B. Smith Jr. served in the Army for 21 years. But Smith faced one of his most life-threatening moments off the ...

Oppenheimer lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Outperform rating on the shares ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on ...

My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce let alone understand. What is cardiac amyloidosis? Am I at risk ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.